GNI Group (3G6) Price & Analysis

Compare

0 Followers

3G6 Stock Chart & Stats

€12.70

€0.40(2.20%)

At close: Jan 08 4:00 PM EST

€12.70

€0.40(2.20%)

Day’s Range― - ―

52-Week Range€8.80 - €26.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€755.31M

Enterprise Value€127.52B

Total Cash (Recent Filing)€22.78B

Total Debt (Recent Filing)€4.97B

Price to Earnings (P/E)―

Beta1.45

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding55,682,068

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-2.00

Price to Book (P/B)4.67

Price to Sales (P/S)7.21

P/FCF Ratio-46.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageA low debt-to-equity ratio implies conservative leverage, giving the company financial flexibility to fund R&D, clinical programs or setbacks without heavy interest burdens. This reduces near-term refinancing risk and supports strategic choices over the next several months.

Healthy Capital StructureA healthy equity ratio signals a solid capital base that can absorb operational volatility common in biotech. It improves resilience to cash-flow swings, supports potential fundraising or partnership negotiations, and helps preserve optionality for multi-quarter development timelines.

Modest Revenue GrowthConsistent top-line growth, even if modest, indicates underlying commercial traction or expanding program revenue. Over a multi-month horizon this supports scaling opportunities and provides a foundation for future margin recovery if operating efficiency improves.

Bears Say

Negative Cash FlowsSustained negative operating and free cash flow erodes runway and forces reliance on external financing or asset sales. This constrains the firm's ability to fund trials or commercialization internally and raises dilution or liquidity risk over the coming quarters.

Declining ProfitabilityNegative EBIT and net margins reflect structural operational challenges and cost intensity relative to revenues. Without meaningful cost base changes or revenue acceleration, profitability is unlikely to normalize, limiting sustainable free cash generation over months ahead.

Negative Return On EquityA negative ROE indicates the company is currently destroying shareholder value and deploying equity inefficiently. This metric undermines investor confidence and may raise the cost or reduce availability of equity financing needed to support long-term programs.

GNI Group News

GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit

GNI Group ( ($JP:2160) ) has issued an update. GNI Group Ltd., a biopharmaceutical company listed on the...

5d ago

GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group reported FY2025 consolidated revenue of ¥26.84 billion,...

5d ago

GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has postponed the disclosure of its full-year...

5d ago

GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has addressed a series of investor questions...

6d ago

3G6 Earnings this Week: How Will it Perform?

GNI Group (3G6) is scheduled to report 4th quarter earnings on 02/13/2026. Regarding Q4 estimates, Wall Street analysts...

7d ago

GNI Group Slashes 2025 Profit Outlook as Cullgen Listing Is Delayed and Impairment Losses Loom

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has sharply revised its full-year 2025 consolidated...

26d ago

GNI Group Makes Dental Lab ZOO LABO a Consolidated Subsidiary to Bolster Japan Medtech Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has acquired all shares of dental laboratory...

1M ago

GNI Subsidiary Cullgen to Showcase Advancing Pipeline at J.P. Morgan Healthcare Conference

GNI Group ( ($JP:2160) ) has shared an update. GNI Group’s U.S.-based consolidated subsidiary Cullgen Inc. will participate...

1M ago

GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China

GNI Group ( ($JP:2160) ) just unveiled an update. GNI Group announced that its subsidiary Gyre Therapeutics has...

1M ago

GNI Group Exits Governance Partners ASIA Fund and Brings Key Holding On-Balance Sheet

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has decided to withdraw from Governance Partners...

2M ago

3G6 FAQ

What was GNI Group Ltd.’s price range in the past 12 months?

GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.

What is GNI Group Ltd.’s market cap?

GNI Group Ltd.’s market cap is €755.31M.

When is GNI Group Ltd.’s upcoming earnings report date?

GNI Group Ltd.’s upcoming earnings report date is May 18, 2026 which is in 89 days.

How were GNI Group Ltd.’s earnings last quarter?

GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.41 earnings per share for the quarter, missing the consensus estimate of €1.238 by -€1.649.

Is GNI Group Ltd. overvalued?

According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GNI Group Ltd. pay dividends?

GNI Group Ltd. does not currently pay dividends.

What is GNI Group Ltd.’s EPS estimate?

GNI Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GNI Group Ltd. have?

GNI Group Ltd. has 55,682,068 shares outstanding.

What happened to GNI Group Ltd.’s price movement after its last earnings report?

GNI Group Ltd. reported an EPS of -€0.41 in its last earnings report, missing expectations of €1.238. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of GNI Group Ltd.?

Currently, no hedge funds are holding shares in DE:3G6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.